Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.55 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4363267 | 0.94 | AKR1B1 (0.60) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL10487936 | 0.91 | TRAP1 (0.55) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL10487983 | 0.88 | TRAP1 (0.52) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL10487924 | 0.86 | TRAP1 (0.53) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL10487948 | 0.84 | ALDH1A1 (0.58) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL10487908 | 0.84 | DDR1 (0.58) | TRAP1HSP90B1HSP90AA1DDR1CA9 | |
| SCHEMBL17242523 | 0.83 | KDM4E (0.56) | OPRM1DDR1CA9CA12ACHE | |
| SCHEMBL10487998 | 0.83 | TRAP1 (0.47) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL10488205 | 0.79 | TRAP1 (0.59) | AKR1A1AKR1B1TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL17242615 | 0.78 | ALDH1A1 (0.52) | TRAP1HSP90B1HSP90AA1DDR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
| EP-0712849-B1 | Process of preparation of substituted quinazolin-2,4-diones | CLARIANT GMBH (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999038497-A2 | OPHTHALMIC COMPOSITION | R-TECH UENO, LTD. (JP) | 1999-08-05 | — | — | WO | disclosed |
| US-5710319-A | Process for the preparation of substituted quinazoline-2,4-diones | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-20 | — | — | US | disclosed |
| EP-0712849-A2 | Process of preparation of substituted quinazolin-2,4-diones | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-22 | — | — | EP | disclosed |
| US-4883800-A | DIABETES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| US-4734419-A | Quinazoline derivatives, compositions thereof and their use in treating diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0218999-A2 | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | AKR1A1 1692/4885AKR1B1 1525/4885TRAP1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.